keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma stage system

keyword
https://www.readbyqxmd.com/read/28746206/association-between-relative-liver-enhancement-on-gadoxetic-acid-enhanced-magnetic-resonance-images-and-histologic-grade-of-hepatocellular-carcinoma
#1
Young-Joo Jin, Soon Gu Cho, Kun Young Lee, Joon Mee Kim, Jin Woo Lee
We evaluated the association between histologic grade of hepatocellular carcinoma (HCC) and degree of HCC enhancement on Gd-EOB-DTPA (Gadoxetic acid, Primovist)-enhanced magnetic resonance images (MRI) in HCC patients.A total of 121 patients who underwent curative surgical resection for HCC at our institution between January 2012 and March 2015 were retrospectively analyzed. Gadoxetic acid enhanced MRI was performed in all patients before surgery. Signal intensities of HCC and peri-HCC areas were measured using regions of interest...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28728985/adjuvant-hepatic-arterial-infusion-chemotherapy-is-beneficial-for-selective-patients-with-hepatocellular-carcinoma-undergoing-surgical-treatment
#2
Jui-Hu Hsiao, Cheng-Chung Tsai, Tsung-Jung Liang, Chia-Ling Chiang, Huei-Lung Liang, I-Shu Chen, Yu-Chia Chen, Po-Ming Chang, Nan-Hua Chou, Being-Whey Wang
BACKGROUND: Recurrence rate after curative surgical resection of Hepatocellular carcinoma (HCC) remains high. Postoperative hepatic arterial infusion chemotherapy (HAIC) has been suggested to improve survival. This study is to investigate the efficacy of HAIC in the patients with poor tumor factors such as vascular invasion or multiplicity. METHODS: From 2006 to 2014, 221 patients with HCC undergoing hepatectomy and pathologically staged as ≧ T2 (American Joint Committee on Cancer TNM staging system, 7th edition) were included...
July 17, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28723861/medicaid-and-uninsured-hepatocellular-carcinoma-patients-have-more-advanced-tumor-stage-and-are-less-likely-to-receive-treatment
#3
Jennifer Wang, John Ha, Aristeo Lopez, Taft Bhuket, Benny Liu, Robert J Wong
GOALS: To evaluate the impact of insurance status on tumor stage at diagnosis, treatment received, and overall survival among adults with hepatocellular carcinoma (HCC). BACKGROUND: Insurance status affects access to care, which impacts timely access to cancer screening for early detection and treatment. STUDY: Using the 2007 to 2012 Surveillance, Epidemiology, and End Results (SEER) database, we retrospectively evaluated US adults with HCC...
July 18, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28706579/conventional-vs-drug-eluting-beads-transarterial-chemoembolization-for-hepatocellular-carcinoma
#4
REVIEW
Jeong Eun Song, Do Young Kim
Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drug-eluting beads (DEBs) have been imposed as novel drug-delivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE...
June 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28698202/sorafenib-in-patients-with-hepatocellular-carcinoma-results-of-the-observational-insight-study
#5
Tom M Ganten, Rudolf E Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder, Peter R Galle, Thomas Göhler, Matthias Walther, Ronald Koschny, Guido Gerken
Sorafenib is the only currently approved systemic therapy for advanced hepatocellular carcinoma (HCC). We aimed to evaluate the safety and efficacy of sorafenib therapy in patients with HCC under real-life conditions regarding patient, tumor characteristics and any adverse events at study entry and at follow-up visits every 2-4 months. <br /><br />Experimental Design: The present INSIGHT study is a non-interventional, prospective, multicenter, observational study performed in 124 sites across Austria and Germany between 2008 and 2014...
July 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28693224/validation-and-ranking-of-seven-staging-systems-of-hepatocellular-carcinoma
#6
Zhan-Hong Chen, Ying-Fen Hong, Jinxiang Lin, Xing Li, Dong-Hao Wu, Jing-Yun Wen, Jie Chen, Dan-Yun Ruan, Qu Lin, Min Dong, Li Wei, Tian-Tian Wang, Ze-Xiao Lin, Xiao-Kun Ma, Xiang-Yuan Wu, Ruihua Xu
The aim of the present study was to evaluate the ability of seven staging systems to predict 3- and 6-month and cumulative survival rates of patients with advanced hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). Data were collected from 220 patients with HBV-associated HCC who did not receive any standard anticancer treatment. Participants were patients at The Third Affiliated Hospital of Sun Yat-sen University from September 2008 to June 2010. The participants were classified according to the Chinese University Prognostic Index (CUPI), the Cancer of the Liver Italian Program (CLIP), Japan Integrated Staging (JIS), China Integrated Score (CIS) systems, Barcelona Clinic Liver Cancer (BCLC), Okuda and tumor-node-metastasis (TNM) staging systems at the time of diagnosis and during patient follow-up...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28685716/gene-variations-of-sixth-complement-component-affecting-tacrolimus-metabolism-in-patients-with-liver-transplantation-for-hepatocellular-carcinoma
#7
Jian-Hua Liao, Chang-Can Li, Shao-Han Wu, Jun-Wei Fan, Hai-Tao Gu, Zhao-Wen Wang
BACKGROUND: Orthotopic liver transplantation (OLT) improves the prognosis of patients with hepatocellular carcinoma (HCC). Moreover, the complement system is a powerful immune effector that can affect liver function and process of liver cirrhosis. However, studies correlating the complement system with tacrolimus metabolism after OLT are scarce. In this study, the role of single nucleotide polymorphisms (SNPs) associated with the sixth complement component (C6) in tacrolimus metabolism was investigated during the early stages of liver transplantation...
July 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28683459/natural-history-of-t1n0m0-hepatocellular-carcinoma-large-scale-study-in-the-united-states
#8
Humaid O Al-Shamsi, Reham Abdel-Wahab, Manal M Hassan, Ahmed S Shalaby, Ibrahim Dahbour, Sahin Lacin, Armeen Mahvash, Bruno C Odisio, Ravi Murthy, Rony Avritscher, Mohamed E Abdelsalam, Asif Rashid, Jean-Nicolas Vauthey, Thomas A Aloia, Claudius Conrad, Yun Shin Chun, Sunil Krishnan, Prajnan Das, Eugene J Koay, Hesham M Amin, James C Yao, Ahmed O Kaseb
BACKGROUND: Hepatocellular carcinoma (HCC) prognosis depends on clinicopathological features in addition to the treatment provided. We aimed to assess the natural history of TNM stage I HCC tumors which received different treatment over a period of 20 years. METHODS: Between 1992 and 2011, a total of 397 stage I HCC patients were included. Detailed information was retrieved from MD Anderson Cancer Center patients' medical records. The Kaplan-Meier method was used to calculate patients' overall survival (OS)...
July 6, 2017: Oncology
https://www.readbyqxmd.com/read/28670891/validation-of-the-hong-kong-liver-cancer-staging-system-in-patients-with-hepatocellular-carcinoma-after-curative-intent-treatment
#9
Alan Chuncharunee, Sith Siramolpiwat
Backgrounds: Recently Hong Kong Liver Cancer (HKLC) staging system has been proposed for staging of hepatocellular carcinoma (HCC), and has been shown to provide better prognostic ability than the Barcelona Clinic Liver Cancer (BCLC) system. However, the HKLC system lacks external validation, and its applicability remains uncertain. The present study was aimed to evaluate the prognostic performance of HKLC in HCC patients treated with curative intent. Methods: Medical records of HCC patients treated with either resection or radiofrequency ablation (RFA) from 2011 to 2016 were retrospectively reviewed...
June 25, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28668842/diagnostic-value-of-systemic-cholesteryl-ester-free-cholesterol-ratio-in-hepatocellular-carcinoma
#10
Sabrina Krautbauer, Thomas S Weiss, Reiner Wiest, Doris Schacherer, Gerhard Liebisch, Christa Buechler
BACKGROUND: Hepatocellular carcinoma (HCC) most commonly occurs in the setting of liver cirrhosis which is characterized by low serum lipids. We hypothesized that composition of lipoproteins and consequently lipid species ratios are mostly unchanged in patients with cirrhosis compared to controls. This approach may be appropriate to identify lipid ratios altered in HCC irrespective of liver dysfunction. PATIENTS AND METHODS: Lipids were measured in serum of 21 patients with HCC, 41 patients with liver cirrhosis and 22 controls...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28652658/barcelona-clinic-liver-cancer-outperforms-hong-kong-liver-cancer-staging-of-hepatocellular-carcinoma-in-multiethnic-asians-real-world-perspective
#11
James Weiquan Li, Boon-Bee George Goh, Pik-Eu Chang, Chee-Kiat Tan
AIM: To compare the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) classification systems when applied to HCC patients from the largest tertiary-level centre in Singapore. METHODS: One thousand two hundred and seventy hepatocellular carcinoma (HCC) patients prospectively enrolled in a tertiary-level centre registry in Singapore since 1988 were studied. Patients were grouped into their respective BCLC and HKLC stages. Data such as demography, aetiology of HCC and type of treatment were collected...
June 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28651303/nomograms-to-predict-the-individual-survival-of-patients-with-solitary-hepatocellular-carcinoma-after-hepatectomy
#12
Junyi Shen, Linye He, Chuan Li, Tianfu Wen, Weixia Chen, Changli Lu, Lvnan Yan, Bo Li, Jiayin Yang
Background/Aims: Solitary hepatocellular carcinoma (HCC) is a subgroup of HCCs. We aimed to establish nomograms for predicting the survival of solitary HCC patients after hepatectomy. Methods: A total of 538 solitary HCC patients were randomly classified into training and validation sets. A Cox model was used to identify predictors of overall survival (OS) in the training set. A nomogram was generated based on these predictors and was validated using the validation set...
June 27, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28648803/sorafenib-in-combination-with-transarterial-chemoembolisation-in-patients-with-unresectable-hepatocellular-carcinoma-tace-2-a-randomised-placebo-controlled-double-blind-phase-3-trial
#13
Tim Meyer, Richard Fox, Yuk Ting Ma, Paul J Ross, Martin W James, Richard Sturgess, Clive Stubbs, Deborah D Stocken, Lucy Wall, Anthony Watkinson, Nigel Hacking, T R Jeffry Evans, Peter Collins, Richard A Hubner, David Cunningham, John Neil Primrose, Philip J Johnson, Daniel H Palmer
BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo. METHODS: We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma...
June 22, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28647765/epidemiology-of-hepatocellular-carcinoma-target-population-for-surveillance-and-diagnosis
#14
REVIEW
An Tang, Oussama Hallouch, Victoria Chernyak, Aya Kamaya, Claude B Sirlin
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer mortality worldwide. Incidence rates of liver cancer vary widely between geographic regions and are highest in Eastern Asia and sub-Saharan Africa. In the United States, the incidence of HCC has increased since the 1980s. HCC detection at an early stage through surveillance and curative therapy has considerably improved the 5-year survival. Therefore, medical societies advocate systematic screening and surveillance of target populations at particularly high risk for developing HCC to facilitate early-stage detection...
June 24, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28638790/evolving-role-of-sorafenib-in-the-management-of-hepatocellular-carcinoma
#15
REVIEW
Ioannis A Ziogas, Georgios Tsoulfas
Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality. Although there is a broad spectrum of treatment options to choose from, only a few patients are eligible candidates to receive a curative therapy according to their stage of disease, and thus palliative treatment is implemented in the majority of the patients suffering from liver cancer. Sorafenib, a multikinase inhibitor, is the only currently approved agent for systemic therapy in patients with advanced stage HCC and early stage liver disease...
June 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28638267/synergistic-antitumor-effect-of-sorafenib-in-combination-with-atm-inhibitor-in-hepatocellular-carcinoma-cells
#16
Jianhua Liu, Yahui Liu, Lingyu Meng, Bai Ji, Daqing Yang
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC patients indicate that sorafenib alone has only moderate antitumor efficacy, and could not inhibit disease metastasis and progression. KU-55933 is a specific ATM inhibitor, which has pro-apoptotic effect on tumor cells. In this study, we analyzed the synergistic effect of sorafenib and KU-55933 on the proliferation of HCC cell lines. Methods: Three HCC cell lines were treated with sorafenib and KU-55933 alone or combination in vitro to investigate inhibitory effect by MTT and wound healing assay...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28636293/-treatment-of-advanced-hepatocellular-carcinoma-novel-agents-and-role-of-local-therapy
#17
Louis Parisod, Rafael Duran, Alban Denys, Antonia Digklia
The incidence of hepatocellular carcinoma (HCC) is increasing in Switzerland and its treatment is a challenge. The purpose of this article is to summarize the different therapeutic approaches in the metastatic stage, as well as the perspectives of targeted treatments and immunotherapy. Until recently, the only recognized therapeutic standard for these patients with metastatic CHC was sorafenib, a tyrosine kinase inhibitor. If the patient was to progress under sorafenib, no other recognized therapeutic option was available as second line...
May 17, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28628497/predicting-short-term-and-long-term-mortality-of-hospitalized-portuguese-patients-with-alcoholic-hepatitis
#18
Samuel R Fernandes, Pedro Marques da Costa, Sofia Vítor, Joana R Carvalho, Patrícia Santos, Carlos M Moura, Helena Cortez-Pinto, Fernando Ramalho, José Velosa
BACKGROUND: Alcohol abuse can result in a spectrum of liver injury that ranges from mild fatty infiltration to alcoholic hepatitis (AH), cirrhosis, and hepatocellular carcinoma. The present study aimed to evaluate current scoring systems in predicting short-term and long-term mortality because of AH. PATIENTS AND METHODS: Records of 170 consecutive patients with AH admitted to a tertiary center between January 2005 and October 2015 were reviewed. Clinical and biochemical parameters were retrieved for the assessment of AH scores for the day of admission (D1) and for the seventh day of hospitalization (D7)...
June 16, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28626732/albumin-bilirubin-albi-grade-as-part-of-the-evidence-based-clinical-practice-guideline-for-hcc-of-the-japan-society-of-hepatology-a-comparison-with-the-liver-damage-and-child-pugh-classifications
#19
Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Hideki Kawasaki, Yoichi Hiasa, Kojiro Michitaka
AIM/BACKGROUND: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. METHODS: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group)...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/28618075/surgical-treatment-for-advanced-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#20
REVIEW
Kazuhiko Sakamoto, Hiroaki Nagano
The Barcelona Clinic Liver Cancer (BCLC) staging system recommends administration of a tyrosine kinase inhibitor (sorafenib) as standard therapy in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). Sorafenib has been shown to prolong median overall survival (OS) by about 3 months in advanced HCC patients with PVTT (8.1 vs 4.9 months). However, its clinical effectiveness is still controversial and standard treatment with sorafenib is not established in Japan. Surgical resection is considered as a potentially curative treatment and provides an acceptable outcome for carefully selected patients...
June 15, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
keyword
keyword
66281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"